Navigation Links
Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Date:8/19/2007

(10,284) (17,599) (20,516) (105,117)

Other income

(expenses):

Interest income 448 1,060 686 1,753 4,560

Interest expense (74) (86) (125) (179) (1,261)

Change in fair

value of warrant

Liability 471 (86) 127 (149) (454)

Other expense 2 - (1) - (1,181)

Loss before

tax benefit (8,624) (9,396) (16,912) (19,091) (103,453)

Income tax benefit - - - - 695

Net loss (8,624) (9,396) (16,912) (19,091) (102,758)

Deemed dividend (19,424) - (19,424) - (19,424)

Preferred stock

accretion (41) (310) (81) (351) (802)

Net loss

attributable

to common

stockholders $(28,089) $(9,706) $(36,417) $(19,442) $(122,984)

Net loss

attributable

to common

stockholders per

common share --

basic and diluted $(39.04) $(1.37) $(57.78) $(4.80)

Weighted-average

common shares

outstanding --

basic and

diluted 719,556 7,083,748 630,230 4,051,709

See accompanying notes to consolidated financial statements

Amicus Therapeutics, Inc

Statement of Operations Information for 3 months ending June 30, 2007

Change in

Fair

Value of Preferred Stock

Warrant Stock Compen- GAAP as

Non-GAAP Liability Accretion sation Reported

Income Statement

Classifications:

Research and development (6,361)
'/>"/>

SOURCE Amicus Therapeutics

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Amicus Therapeutics Presents Positive Results From Phase 1 Clinical Studies of Plicera for Gaucher Disease
2. Amicus Therapeutics Presents Preclinical Data from Studies of Plicera for Gaucher Disease
3. Amicus Therapeutics Presents Data From Preclinical and Phase 1 Studies of Amigal for Fabry Disease
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
8. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
9. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
10. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
11. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/8/2008)...ts for Spinal Cord, Other Nerve,Injuries -, PHILA...in that enables,nerve cells to communicate with ea...oping nervous system. Research into how that prote...ells may provide a basis for eventual,treatments f...ystem,including spinal cord injury., "This expan...
(Date:10/8/2008)...-ICR as Vaccine Adjuvant, SAN DIEGO, Oct. 8 /PRNe...poration (TSX: NVN) today presented positive data ...l-like Receptor 3 agonist, Poly IC-Poly,Arginine (...yon, France.,Study results demonstrated Poly-ICR t...like Receptor 3 (TLR3) pathway. Data showed that,P...
(Date:10/7/2008)... for detecting polyps that can be ...ct. 7 /- At the American College of,G...do (ACG 2008), renowned,gastroenterologist Douglas...tional clinical study that evaluated the efficacy ...at is designed to improve the ability,of physician...
(Date:10/7/2008)...all/ -- CEL-SCI Corporation,(NYSE: CVM ) announce...er,Agreement (MTA) with the National Institutes of... of Dr. Francesco M. Marincola, M.D., to,investiga...roenvironment,caused by CEL-SCI,s cancer drug Mult...s Disease and Immunogentics Section, Department of...
Breaking Medicine Technology:Protein Shown to Play a Key Role in Normal Development of Nervous System 2Protein Shown to Play a Key Role in Normal Development of Nervous System 3Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 2Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 3Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 4Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 5National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 2National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 3National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 4National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 5CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 2CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 3Mom You Rock 21 17145 1What You Dont Know Could Hurt You 17142 1What You Dont Know Could Hurt You 17142 2What You Dont Know Could Hurt You 17142 3Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research 4690 1Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research 4690 2Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research 4690 3Breast Feeding While on Seizure Meds Doesnt Harm Babies 17141 1Breast Feeding While on Seizure Meds Doesnt Harm Babies 17141 2
...9, 2007 - Pfizer said today that,results showing p...melanoma, thyroid, liver, non-small cell lung (NSC...C) - a type of advanced kidney,cancer - will be pr...cal Oncology (ASCO) annual meeting in Chicago., "E...atment, so,it,s critical that physicians have the ...
...07 /PRNewswire/ -- Phase II,results exceed expecta...TM) , Australian drug development company Alchemia...d and Drug Administration (FDA),following the succ...f its metastatic colorectal cancer treatment, HyCA... II clinical trial in 80,patients with metastatic ...
Other Medicine Technology:New Pfizer Oncology Data Across Numerous Cancer Types to be,Presented at ASCO 2New Pfizer Oncology Data Across Numerous Cancer Types to be,Presented at ASCO 3New Pfizer Oncology Data Across Numerous Cancer Types to be,Presented at ASCO 4New Pfizer Oncology Data Across Numerous Cancer Types to be,Presented at ASCO 5Positive Final Data from HyCAMP Phase II Trial in Metastatic,Colorectal 2Positive Final Data from HyCAMP Phase II Trial in Metastatic,Colorectal 3Positive Final Data from HyCAMP Phase II Trial in Metastatic,Colorectal 4
(Date:10/10/2008)...Coach Holly Warlick Teams Up with Legal and Medica...Ever Cancer and Careers Seminar in,Knoxville, KNO...ion of National,Breast Cancer Awareness Month, Can...e joined forces with YWCA Knoxville, The Wellness ...e Holly Warlick, University of Tennessee,women,s b...
(Date:10/10/2008)... The Healthcare Technology Ev... , Exton, PA (PRWEB) Sept...ey Chapters of the national Healthcare Information...forces to bring regional health information techno... conference entitled The Healthcare Technology Evo...
(Date:10/10/2008)...ston, MABoston Medical Center (BMC) has received a...l Institute on Aging (NIA) to fund the Boston Clau...BMC,s Pepper Center is one of only 11 Pepper Cente... Americans Independence Center Program was establi...enator from Florida. During his five decades of pu...
(Date:10/10/2008)...olecular CT adds metabolic information from PET to...gnostic imaging for maximized workflow ...ICH, Germany, Oct. 10 /PRNewswire/ -- Siemens Heal...duces molecular CT, a new concept in,integrated im...d is a,practical solution for today,s shrinking he...
Breaking Medicine News(10 mins):Health News:Local Experts Help Women Living and Working with Cancer Even the Score 2Health News:Local Experts Help Women Living and Working with Cancer Even the Score 3Health News:Local Experts Help Women Living and Working with Cancer Even the Score 4Health News:HIMSS New Jersey and Delaware Valley Chapters Sponsor Regional Conference 2Health News:Boston Medical Center receives $5.8m grant 2Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 2Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 3Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 4
...e denied life-changing operations unless they agre...ash-strapped hospitals say that they will not trea...hey are going to give up on smoking. Those who do ... treatment. Smokers are at a big risk of complic...
...ers in good health should not be discouraged from ...act a 16-year study of nearly 9,000 men in the US ... of heart attack. The studies showed that men who...its of alcohol every day on average demonstrated n...
...wenty-three percent of patients showed evidence of...ment in a new study measuring drug-induced liver//...medications are the most common prescription medic...ng to data from a prospective trial conducted by t...
...r has said that Ottawa would invest $8.4-million o...ealth strategy.// Tony Clement said that the mone...of cardiovascular disease in Canada, particularly ... plan of attack could be formulated. He said, "To...
Other Medicine News:Health News:Smokers Warned to Give up else Face Denial of Operations 2Health News:Smokers Warned to Give up else Face Denial of Operations 3Health News:Some Prescriptions Can Lead to Chronic Drug-Induced Liver Injury 2
...onal reference laboratory and a worldwide leader i...ARUP offers an extensive test menu of highly compl...ic pathology. Owned by the University of Utah, ARU...the nation's university teaching hospitals and chi...
...onal reference laboratory and a worldwide leader i...ARUP offers an extensive test menu of highly compl...ic pathology. Owned by the University of Utah, ARU...the nation's university teaching hospitals and chi...
...onal reference laboratory and a worldwide leader i...ARUP offers an extensive test menu of highly compl...ic pathology. Owned by the University of Utah, ARU...the nation's university teaching hospitals and chi...
...onal reference laboratory and a worldwide leader i...ARUP offers an extensive test menu of highly compl...ic pathology. Owned by the University of Utah, ARU...the nation's university teaching hospitals and chi...
Medicine Products: